Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6256195 | 0.84 | KDM4E (0.57) | KDM4EKMT2AMEN1METAP2ESR1 | |
| SCHEMBL28539195 | 0.84 | PDE10A (0.62) | PDE10AKDM4EKMT2AMEN1PDE1A | |
| SCHEMBL10913571 | 0.81 | KDM4E (0.54) | KDM4EKMT2AMEN1METAP2ESR1 | |
| SCHEMBL16597147 | 0.80 | PDE10A (0.57) | PDE10AKDM4EKMT2AMEN1PDE1A | |
| SCHEMBL2858652 | 0.80 | KDM4E (0.49) | PDE10AKDM4EKMT2AMEN1POLB | |
| SCHEMBL17091595 | 0.78 | KMT2A (0.38) | PDE10AKDM4EKMT2AMEN1METAP2 | |
| SCHEMBL7117069 | 0.78 | PDE10A (0.54) | PDE10AKDM4EKMT2AMEN1PDE1A | |
| SCHEMBL4164856 | 0.78 | PDE10A (0.54) | PDE10AKDM4EKMT2AMEN1PDE1A | |
| SCHEMBL28448323 | 0.77 | KDM4E (0.50) | KDM4EKMT2AMEN1METAP2ESR1 | |
| SCHEMBL3112677 | 0.77 | KMT2A (0.64) | PDE10AKDM4EKMT2AMEN1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617336-B1 | Treatment of urinary incontinence, venous insufficiency, migraine or gastrointestinal disorders | SANOFI-SYNTHELABO (FR) | 2003-09-09 | — | — | US | disclosed |
| US-20030097000-A1 | 2-Phenyl-quinoline derivatives, preparation method and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2003-05-22 | — | — | US | disclosed |
| EP-1242381-A2 | 2-PHENYL-QUINOLINE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-09-25 | — | — | EP | disclosed |
| EP-1240146-A1 | 2-ARYLQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044197-A2 | 2-PHENYL-QUINOLINE DERIVATIVES AND THEIR USE AS CONTRACTING AGENT FOR SMOOTH MUSCLES | SANOFI-SYNTHELABO (FR) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001038310-A1 | 2-ARYLQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030097000-A1 | 2-Phenyl-quinoline derivatives, preparation method and therapeutic use thereof | CYP2F1, CYP4F2, CYP4F3 | PDE10A 2739/4885KDM4E 3450/4885KMT2A 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.